- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
UPTRAVI® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy
STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
55.2 percent of patients were in symptomatic remission and 96.4 percent of patients were corticosteroid-free at week 152 New data from the UNIFI study is one of 22 Janssen abstracts, including five oral and three digital oral presentations, at the 16th Congress of the European Crohn’s and Colitis Organisation
Johnson & Johnson Launches Network of Global Health Discovery Centers that Aim to Speed Up Science and Tackle Pandemic Threats
J&J Centers for Global Health Discovery (J&J Centers) are a new cornerstone of the Company’s efforts to solve the world’s most pressing health challenges The first J&J Satellite Center is hosted at the London School of Hygiene & Tropical Medicine (LSHTM) and focused on addressing the threat of antimicrobial resistance and tuberculosis J&J Centers will include collaborations with renowned academic institutions that accelerate potentially lifesaving innovations from the lab to the last mile
Janssen Submits New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
Application seeks two pediatric indications, including an age-appropriate new weight-based oral suspension formulation to help minimize dosing errors If approved, XARELTO® will be the first and only oral Factor Xa inhibitor indicated in the U.S. for use in appropriate pediatric patients
New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress
New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
57.7 percent achieved ≥20 percent improvement in joint symptoms (ACR20) and 53.4 percent achieved complete skin clearance (PASI 100) at one year in COSMOS, the first study of a selective interleukin (IL)-23 inhibitor in a true TNFi-IR patient population Of 34 Janssen abstracts at the European League Against Rheumatism (EULAR) E-Congress, many present efficacy and safety data for TREMFYA in treating adults with active PsA
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
- Clinical Data from More Than 10 Approved and Investigational Treatments for Solid Tumors and Hematologic Malignancies to be Presented During the 2021 ASCO Annual Meeting - Multiple Myeloma and Chronic Lymphocytic Leukemia Data to be Featured During EHA 2021 Virtual Congress